Selective localization of a radioiodinated phospholipid ether analog in human tumor xenografts

K. P. Plotzke, S. J. Fisher, R. L. Wahl, N. M. Olken, S. Skinner, M. D. Gross, R. E. Counsell

Research output: Contribution to journalArticle

Abstract

Administration of [125I]-rac-1-O-[12-(m-iodophenyl)dodecyl-2-O- methylglycero-3-phosphocholine (NM-294) to athymic mice implanted with human tumors of several histologies, including adenocarcinoma of the ovary and colon, melanoma and small-cell carcinoma of the lung, resulted in excellent images of the tumors by gamma camera scintigraphy. Images of the tumor were obtained at 5 days or more postinjection, by which time nearly all background activity had cleared from the liver and gastrointestinal tract. Tumor-to- blood ratios at this time were quite high and ranged from approximately 8:1 (melanoma) to 30:1 (ovarian carcinoma), which is consistent with the scintigraphic images obtained in all human tumor models. Lipid extraction of the liver and tumor at 13 days postinjection showed that most of the radioactivity in these tissues remained associated with the parent compound, with only a small amount retained by the liver. Appropriately radioiodinated NM-294 has substantial potential as a tumor-avid radiopharmaceutical.

Original languageEnglish (US)
Pages (from-to)787-792
Number of pages6
JournalJournal of Nuclear Medicine
Volume34
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

Phospholipid Ethers
Heterografts
Neoplasms
Liver
Melanoma
Gamma Cameras
Phosphorylcholine
Radiopharmaceuticals
Small Cell Lung Carcinoma
Nude Mice
Radionuclide Imaging
Radioactivity
Gastrointestinal Tract
Ovary
Histology
Colon
Adenocarcinoma
Carcinoma
Lipids

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Plotzke, K. P., Fisher, S. J., Wahl, R. L., Olken, N. M., Skinner, S., Gross, M. D., & Counsell, R. E. (1993). Selective localization of a radioiodinated phospholipid ether analog in human tumor xenografts. Journal of Nuclear Medicine, 34(5), 787-792.

Selective localization of a radioiodinated phospholipid ether analog in human tumor xenografts. / Plotzke, K. P.; Fisher, S. J.; Wahl, R. L.; Olken, N. M.; Skinner, S.; Gross, M. D.; Counsell, R. E.

In: Journal of Nuclear Medicine, Vol. 34, No. 5, 1993, p. 787-792.

Research output: Contribution to journalArticle

Plotzke, KP, Fisher, SJ, Wahl, RL, Olken, NM, Skinner, S, Gross, MD & Counsell, RE 1993, 'Selective localization of a radioiodinated phospholipid ether analog in human tumor xenografts', Journal of Nuclear Medicine, vol. 34, no. 5, pp. 787-792.
Plotzke KP, Fisher SJ, Wahl RL, Olken NM, Skinner S, Gross MD et al. Selective localization of a radioiodinated phospholipid ether analog in human tumor xenografts. Journal of Nuclear Medicine. 1993;34(5):787-792.
Plotzke, K. P. ; Fisher, S. J. ; Wahl, R. L. ; Olken, N. M. ; Skinner, S. ; Gross, M. D. ; Counsell, R. E. / Selective localization of a radioiodinated phospholipid ether analog in human tumor xenografts. In: Journal of Nuclear Medicine. 1993 ; Vol. 34, No. 5. pp. 787-792.
@article{e7094e8ea4904d2d9858d85ee0ff636f,
title = "Selective localization of a radioiodinated phospholipid ether analog in human tumor xenografts",
abstract = "Administration of [125I]-rac-1-O-[12-(m-iodophenyl)dodecyl-2-O- methylglycero-3-phosphocholine (NM-294) to athymic mice implanted with human tumors of several histologies, including adenocarcinoma of the ovary and colon, melanoma and small-cell carcinoma of the lung, resulted in excellent images of the tumors by gamma camera scintigraphy. Images of the tumor were obtained at 5 days or more postinjection, by which time nearly all background activity had cleared from the liver and gastrointestinal tract. Tumor-to- blood ratios at this time were quite high and ranged from approximately 8:1 (melanoma) to 30:1 (ovarian carcinoma), which is consistent with the scintigraphic images obtained in all human tumor models. Lipid extraction of the liver and tumor at 13 days postinjection showed that most of the radioactivity in these tissues remained associated with the parent compound, with only a small amount retained by the liver. Appropriately radioiodinated NM-294 has substantial potential as a tumor-avid radiopharmaceutical.",
author = "Plotzke, {K. P.} and Fisher, {S. J.} and Wahl, {R. L.} and Olken, {N. M.} and S. Skinner and Gross, {M. D.} and Counsell, {R. E.}",
year = "1993",
language = "English (US)",
volume = "34",
pages = "787--792",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "5",

}

TY - JOUR

T1 - Selective localization of a radioiodinated phospholipid ether analog in human tumor xenografts

AU - Plotzke, K. P.

AU - Fisher, S. J.

AU - Wahl, R. L.

AU - Olken, N. M.

AU - Skinner, S.

AU - Gross, M. D.

AU - Counsell, R. E.

PY - 1993

Y1 - 1993

N2 - Administration of [125I]-rac-1-O-[12-(m-iodophenyl)dodecyl-2-O- methylglycero-3-phosphocholine (NM-294) to athymic mice implanted with human tumors of several histologies, including adenocarcinoma of the ovary and colon, melanoma and small-cell carcinoma of the lung, resulted in excellent images of the tumors by gamma camera scintigraphy. Images of the tumor were obtained at 5 days or more postinjection, by which time nearly all background activity had cleared from the liver and gastrointestinal tract. Tumor-to- blood ratios at this time were quite high and ranged from approximately 8:1 (melanoma) to 30:1 (ovarian carcinoma), which is consistent with the scintigraphic images obtained in all human tumor models. Lipid extraction of the liver and tumor at 13 days postinjection showed that most of the radioactivity in these tissues remained associated with the parent compound, with only a small amount retained by the liver. Appropriately radioiodinated NM-294 has substantial potential as a tumor-avid radiopharmaceutical.

AB - Administration of [125I]-rac-1-O-[12-(m-iodophenyl)dodecyl-2-O- methylglycero-3-phosphocholine (NM-294) to athymic mice implanted with human tumors of several histologies, including adenocarcinoma of the ovary and colon, melanoma and small-cell carcinoma of the lung, resulted in excellent images of the tumors by gamma camera scintigraphy. Images of the tumor were obtained at 5 days or more postinjection, by which time nearly all background activity had cleared from the liver and gastrointestinal tract. Tumor-to- blood ratios at this time were quite high and ranged from approximately 8:1 (melanoma) to 30:1 (ovarian carcinoma), which is consistent with the scintigraphic images obtained in all human tumor models. Lipid extraction of the liver and tumor at 13 days postinjection showed that most of the radioactivity in these tissues remained associated with the parent compound, with only a small amount retained by the liver. Appropriately radioiodinated NM-294 has substantial potential as a tumor-avid radiopharmaceutical.

UR - http://www.scopus.com/inward/record.url?scp=0027197173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027197173&partnerID=8YFLogxK

M3 - Article

C2 - 8386759

AN - SCOPUS:0027197173

VL - 34

SP - 787

EP - 792

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 5

ER -